Osteoporosi postmenopausale. Approcci terapeutici

P. Affinito, S. Palomba, C. Sorrentino, M. Pellicano, R. Morgera, C. Nappi

Research output: Contribution to journalArticle

Abstract

The preventive and therapeutical measures to be implemented the post-menopausal osteoporosis are varied, although there is no clear, single protocol of intervention. Estrogens and progestogens. It si verify that the administration of estrogens and/or progestogens prevents bone loss with an action on mineral components of bone and on collagenic metabolism. Bisphosphonates. Operate inhibiting mineralization and, particularly, bone reabsorption. At present its use, in low dosages, is reserved to 'fast bone loser' patients. Calcitonin. It increases bone mass and significantly reduces the frequency of fractures in comparison with only calcium, but its use is limited by high costs. Ipriflavone. Anti-reabsob, ting effects has on bone and stimulates osteoblastic activity; besides, it seems to developd the effect of estrogens on the bone. Fluorides. Fluorides also operate on both components of bone turnover, with a most important action on bone formation. An interesting approach is the association of low doses of monofluorophosphate with calcium. However, further confirmation of the 'quality' of neoformated bone is necessary. Calcium. Calcium supplementation is obligatory where the alimentary supply of calcium is lower then 1 g/die or where an osteomalacic component coexists; only dosages higher than 15 g/die can produce/pharmacological effects on bone turnover. Calcitriol. The use is still disputed. The calcitriol-calcium association seems convincing haveved. Org OD 14. The efficacy of this synthetic steroid to prevent bone loss is probably superimposable on the efficacy of classic estrogen therapy.

Original languageEnglish
Pages (from-to)109-120
Number of pages12
JournalMinerva Ginecologica
Volume49
Issue number3
Publication statusPublished - Mar 1997

Fingerprint

Bone and Bones
Calcium
Estrogens
tibolone
Calcitriol
Bone Remodeling
fluorophosphate
Progestins
Fluorides
Tolnaftate
Physiologic Calcification
Postmenopausal Osteoporosis
Diphosphonates
Calcitonin
Osteogenesis
Minerals
Steroids
Pharmacology
Costs and Cost Analysis
Therapeutics

Keywords

  • Bone loss
  • Osteoporosis
  • Postmenopause
  • Therapy

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Affinito, P., Palomba, S., Sorrentino, C., Pellicano, M., Morgera, R., & Nappi, C. (1997). Osteoporosi postmenopausale. Approcci terapeutici. Minerva Ginecologica, 49(3), 109-120.

Osteoporosi postmenopausale. Approcci terapeutici. / Affinito, P.; Palomba, S.; Sorrentino, C.; Pellicano, M.; Morgera, R.; Nappi, C.

In: Minerva Ginecologica, Vol. 49, No. 3, 03.1997, p. 109-120.

Research output: Contribution to journalArticle

Affinito, P, Palomba, S, Sorrentino, C, Pellicano, M, Morgera, R & Nappi, C 1997, 'Osteoporosi postmenopausale. Approcci terapeutici', Minerva Ginecologica, vol. 49, no. 3, pp. 109-120.
Affinito P, Palomba S, Sorrentino C, Pellicano M, Morgera R, Nappi C. Osteoporosi postmenopausale. Approcci terapeutici. Minerva Ginecologica. 1997 Mar;49(3):109-120.
Affinito, P. ; Palomba, S. ; Sorrentino, C. ; Pellicano, M. ; Morgera, R. ; Nappi, C. / Osteoporosi postmenopausale. Approcci terapeutici. In: Minerva Ginecologica. 1997 ; Vol. 49, No. 3. pp. 109-120.
@article{287a380b0501496ea592c9bf4f5d4e72,
title = "Osteoporosi postmenopausale. Approcci terapeutici",
abstract = "The preventive and therapeutical measures to be implemented the post-menopausal osteoporosis are varied, although there is no clear, single protocol of intervention. Estrogens and progestogens. It si verify that the administration of estrogens and/or progestogens prevents bone loss with an action on mineral components of bone and on collagenic metabolism. Bisphosphonates. Operate inhibiting mineralization and, particularly, bone reabsorption. At present its use, in low dosages, is reserved to 'fast bone loser' patients. Calcitonin. It increases bone mass and significantly reduces the frequency of fractures in comparison with only calcium, but its use is limited by high costs. Ipriflavone. Anti-reabsob, ting effects has on bone and stimulates osteoblastic activity; besides, it seems to developd the effect of estrogens on the bone. Fluorides. Fluorides also operate on both components of bone turnover, with a most important action on bone formation. An interesting approach is the association of low doses of monofluorophosphate with calcium. However, further confirmation of the 'quality' of neoformated bone is necessary. Calcium. Calcium supplementation is obligatory where the alimentary supply of calcium is lower then 1 g/die or where an osteomalacic component coexists; only dosages higher than 15 g/die can produce/pharmacological effects on bone turnover. Calcitriol. The use is still disputed. The calcitriol-calcium association seems convincing haveved. Org OD 14. The efficacy of this synthetic steroid to prevent bone loss is probably superimposable on the efficacy of classic estrogen therapy.",
keywords = "Bone loss, Osteoporosis, Postmenopause, Therapy",
author = "P. Affinito and S. Palomba and C. Sorrentino and M. Pellicano and R. Morgera and C. Nappi",
year = "1997",
month = "3",
language = "English",
volume = "49",
pages = "109--120",
journal = "Minerva Ginecologica",
issn = "0026-4784",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "3",

}

TY - JOUR

T1 - Osteoporosi postmenopausale. Approcci terapeutici

AU - Affinito, P.

AU - Palomba, S.

AU - Sorrentino, C.

AU - Pellicano, M.

AU - Morgera, R.

AU - Nappi, C.

PY - 1997/3

Y1 - 1997/3

N2 - The preventive and therapeutical measures to be implemented the post-menopausal osteoporosis are varied, although there is no clear, single protocol of intervention. Estrogens and progestogens. It si verify that the administration of estrogens and/or progestogens prevents bone loss with an action on mineral components of bone and on collagenic metabolism. Bisphosphonates. Operate inhibiting mineralization and, particularly, bone reabsorption. At present its use, in low dosages, is reserved to 'fast bone loser' patients. Calcitonin. It increases bone mass and significantly reduces the frequency of fractures in comparison with only calcium, but its use is limited by high costs. Ipriflavone. Anti-reabsob, ting effects has on bone and stimulates osteoblastic activity; besides, it seems to developd the effect of estrogens on the bone. Fluorides. Fluorides also operate on both components of bone turnover, with a most important action on bone formation. An interesting approach is the association of low doses of monofluorophosphate with calcium. However, further confirmation of the 'quality' of neoformated bone is necessary. Calcium. Calcium supplementation is obligatory where the alimentary supply of calcium is lower then 1 g/die or where an osteomalacic component coexists; only dosages higher than 15 g/die can produce/pharmacological effects on bone turnover. Calcitriol. The use is still disputed. The calcitriol-calcium association seems convincing haveved. Org OD 14. The efficacy of this synthetic steroid to prevent bone loss is probably superimposable on the efficacy of classic estrogen therapy.

AB - The preventive and therapeutical measures to be implemented the post-menopausal osteoporosis are varied, although there is no clear, single protocol of intervention. Estrogens and progestogens. It si verify that the administration of estrogens and/or progestogens prevents bone loss with an action on mineral components of bone and on collagenic metabolism. Bisphosphonates. Operate inhibiting mineralization and, particularly, bone reabsorption. At present its use, in low dosages, is reserved to 'fast bone loser' patients. Calcitonin. It increases bone mass and significantly reduces the frequency of fractures in comparison with only calcium, but its use is limited by high costs. Ipriflavone. Anti-reabsob, ting effects has on bone and stimulates osteoblastic activity; besides, it seems to developd the effect of estrogens on the bone. Fluorides. Fluorides also operate on both components of bone turnover, with a most important action on bone formation. An interesting approach is the association of low doses of monofluorophosphate with calcium. However, further confirmation of the 'quality' of neoformated bone is necessary. Calcium. Calcium supplementation is obligatory where the alimentary supply of calcium is lower then 1 g/die or where an osteomalacic component coexists; only dosages higher than 15 g/die can produce/pharmacological effects on bone turnover. Calcitriol. The use is still disputed. The calcitriol-calcium association seems convincing haveved. Org OD 14. The efficacy of this synthetic steroid to prevent bone loss is probably superimposable on the efficacy of classic estrogen therapy.

KW - Bone loss

KW - Osteoporosis

KW - Postmenopause

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=0030933394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030933394&partnerID=8YFLogxK

M3 - Article

C2 - 9173338

AN - SCOPUS:0030933394

VL - 49

SP - 109

EP - 120

JO - Minerva Ginecologica

JF - Minerva Ginecologica

SN - 0026-4784

IS - 3

ER -